• Explore /
  • Poster
  • / The interconnection between cellular metabolism and lymphocyte activation as a prognostic factor in patients affected by metastatic pancreatic ductal adenocarcinoma treated with gemcitabine and nab-paclitaxel as first line.

The interconnection between cellular metabolism and lymphocyte activation as a prognostic factor in patients affected by metastatic pancreatic ductal adenocarcinoma treated with gemcitabine and nab-paclitaxel as first line.

Abstract Poster

Authors

Andrea Pretta

Andrea Pretta

Medical Oncology Unit, University Hospital and University of Cagliari, Cagliari, Italy;

Andrea Pretta , Clelia Donisi , Riccardo Giampieri , Pina Ziranu , Erika Cimbro , Dario Spanu , Federica Pecci , Marco Migliari , Francesca Balconi , Alessio Lupi , Enrico Palmas , Giulia Deias , Benedetta Congiu , Marta Pozzari , Sara Murgia , Pusceddu Valeria , Marco Puzzoni , Eleonora Lai , Rossana Berardi , Mario Scartozzi

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract

Track

Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer

Sub Track

Tumor Biology, Biomarkers, and Pathology

Citation

J Clin Oncol 41, 2023 (suppl 4; abstr 752)

DOI

10.1200/JCO.2023.41.4_suppl.752

Abstract #

752

Poster Bd #

M19

Abstract Disclosures

Similar Posters

First Author: John Davelaar

First Author: Mitsuho Imai

First Author: Kedar Kirtane

Poster

2024 ASCO Gastrointestinal Cancers Symposium

Clinical impact of <em>KRAS</em> mutations in metastatic pancreatic ductal adenocarcinoma (PDAC).

Clinical impact of KRAS mutations in metastatic pancreatic ductal adenocarcinoma (PDAC).

First Author: Carter Norton